Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
16 Apr 24
8-K
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
16 Apr 24
8-K
Other Events
1 Apr 24
8-K
Intra-cellular Therapies Announces Executive Appointments and Leadership Changes
19 Mar 24
8-K
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
22 Feb 24
8-K
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
2 Nov 23
8-K
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
8-K
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
18 Apr 24
424B5
Prospectus supplement for primary offering
16 Apr 24
S-3ASR
Automatic shelf registration
16 Apr 24
424B5
Prospectus supplement for primary offering
5 Jan 22
424B5
Prospectus supplement for primary offering
3 Jan 22
424B5
Prospectus supplement for primary offering
11 Sep 20
424B5
Prospectus supplement for primary offering
9 Sep 20
S-8
Registration of securities for employees
10 Aug 20
S-8
Registration of securities for employees
2 Mar 20
424B5
Prospectus supplement for primary offering
8 Jan 20
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
20 Apr 21
PRE 14A
Preliminary proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
13 May 20
DEFA14A
Additional proxy soliciting materials
9 Apr 20
Other
EFFECT
Notice of effectiveness
13 Sep 19
CORRESP
Correspondence with SEC
10 Sep 19
UPLOAD
Letter from SEC
10 Sep 19
CT ORDER
Confidential treatment order
5 Jul 19
CT ORDER
Confidential treatment order
31 Mar 17
UPLOAD
Letter from SEC
9 Feb 17
CORRESP
Correspondence with SEC
19 Jan 17
UPLOAD
Letter from SEC
29 Dec 16
EFFECT
Notice of effectiveness
14 Sep 16
UPLOAD
Letter from SEC
13 Sep 16
Ownership
4
NOSTRAND ROBERT L VAN
2 Apr 24
4
RORY B RIGGS
2 Apr 24
4
RORY B RIGGS
22 Mar 24
4
Sharon Mates
11 Mar 24
4
Lawrence J. Hineline
11 Mar 24
4
Michael Halstead
11 Mar 24
4
Mark Neumann
11 Mar 24
4
Suresh K. Durgam
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24